President and Chief Executive Officer
Mr. Garland joined Portola in October 2018 as president and chief executive officer. He brings more than 2 decades of broad executive leadership experience to Portola, including a strong track record driving multiple billion-dollar product launches.
Mr. Garland joined Portola from Relypsa, Inc., where he was president and previously chief commercial officer. During his tenure, Mr. Garland was responsible for the integration and growth of the US operations after Relypsa was acquired by Vifor Pharma Group in 2016.
Prior to Relypsa, Mr. Garland was executive vice president and chief commercial officer of Exelixis, Inc., where he led global commercial operations and directed sales, marketing, and market access in the United States. Previously, Mr. Garland spent close to a decade at Genentech leading full-scale commercial franchises for 2 top-selling therapies, Avastin® (bevacizumab) and Rituxan® (rituximab). He started his career at Merck as a sales representative and then went on to serve at Amgen in various sales and marketing roles, including market development, to support the launch of Aranesp® (darbepoetin alfa).
Mr. Garland has a B.S. in biological sciences from California Polytechnic State University, San Luis Obispo, and an M.B.A. from Duke University’s Fuqua School of Business. Mr. Garland is a member of the Board of Directors for Karyopharm Therapeutics, a company focused on hematologic diseases and oncology.
Mardi C. Dier
Executive Vice President, Chief Financial Officer and Chief Business Officer
Mardi Dier joined Portola in August 2006 as senior vice president and chief financial officer and has served as executive vice president and chief financial officer since November 2013. She was appointed chief business officer in 2018. Ms. Dier is responsible for leading the corporate finance, accounting, information technology, global supply chain, business development, investor relations, and corporate communications functions. During her tenure at Portola, she has successfully led a series of private, public, and alternative financings and helped lead the company through its pivotal transition into a commercial organization. Previously, she served as vice president of investor relations at Chiron Corporation from 2003 until its acquisition by Novartis Pharmaceuticals in April 2006. Prior to joining Chiron, she served as a director in the West Coast investment banking practice at Prudential Securities, where she focused on client development, equity underwriting, and mergers and acquisitions for biotechnology and other life sciences companies. Ms. Dier began her finance career in the audit department of KPMG Peat Marwick.
She holds a B.S. in biology from Stanford University and an M.B.A. from the Anderson School at the University of California, Los Angeles. Ms. Dier is a member of the board of directors of Adamas Pharmaceuticals, Inc., a company focused on chronic neurological diseases, and ORIC Pharmaceuticals, Inc., a company focused on cancer treatments that address mechanisms of therapeutic resistance.
Executive Vice President, Chief Commercial Officer
Sheldon Koenig joined Portola in 2019 and is responsible for leading the Company’s commercial operations. Prior to joining Portola, Mr. Koenig was senior vice president and head of the cardiovascular franchise for Sanofi, where he led the US business operations and global product launches in more than 20 countries. Previously, he served as vice president and global brand leader for the cardiovascular division of Merck & Co, Inc. where, for more than 25 years, he took on roles of increasing responsibility within the company’s cardiovascular and thrombosis franchises. He has significant overall experience in primary care, specialist, and hospital markets, as well as business development and licensing. Mr. Koenig holds a B.S. from Drexel University and an M.B.A. from Monmouth University.
Executive Vice President, Chief Human Resources Officer
Ernie Meyer joined Portola as executive vice president, chief human resources officer in 2018. In this role, Mr. Meyer is responsible for the development and execution of the global human resources strategy to drive and deliver on business results aligned with the Company’s strategy, goals, and values. He also serves as a member of Portola’s Executive Committee.
Mr. Meyer joins Portola from Celgene, where he spent more than 13 years in positions of increasing scope and responsibility. Most recently, Mr. Meyer served as executive vice president of human resources and corporate services and played a significant role in the company’s growth and expansion from approximately 700 employees in 2 countries to more than 7,000 employees in 37 countries. His experience and expertise extend across the spectrum of human resources, including talent development, diversity, and culture initiatives, new business integration, geographic expansions, and innovative total rewards strategies. Prior to joining Celgene, Mr. Meyer held various global rewards leadership roles at Motorola and The Travelers Insurance Company.
Mr. Meyer holds a B.S. in Business Management with a concentration in Management Information Systems from Widener University.
Executive Vice President, General Counsel and Secretary
John B. Moriarty, Jr., J.D., joined Portola as executive vice president, general counsel, and secretary in 2018. In this role, Mr. Moriarty serves as Portola’s chief legal officer, responsible for leading all legal, regulatory, governance, and compliance initiatives. He is directly involved in strategic business transactions and corporate expansion as a member of Portola’s Executive Committee.
Prior to joining Portola, Mr. Moriarty was executive vice president, general counsel for Alexion Pharmaceuticals, where he was responsible for overseeing all global legal matters spanning 50 countries, as well as managing Alexion’s Global Government Affairs and Global Corporate Communications teams. Previously, he was senior vice president, general counsel, and chief legal officer at Elan Corporation plc, and served as a member of Elan’s Executive Management team. Prior to Elan, Mr. Moriarty held positions of increasing responsibility and leadership at Amgen. Early in his career, Mr. Moriarty worked as an attorney in the healthcare practice of a national law firm’s Washington, DC and New York offices, and was a healthcare fraud prosecutor in the US Attorney’s office and the Virginia Attorney General’s office.
Mr. Moriarty holds a J.D. from the University of Georgia School of Law, cum laude, and a B.A. from the University of Virginia, with distinction. He has served on the board of trustees for the American Kidney Fund since 2015.
Executive Vice President, Chief Technical Operations Officer
Glenn Brame joined Portola as senior vice president of technical operations in 2018. In this role, Mr. Brame is responsible for leading the Company’s technical operations including process development, manufacturing, supply chain, quality assurance, and end-to-end process and platform optimization for Portola’s entire portfolio. He also serves as a member of Portola’s Executive Committee, contributing directly to global expansion efforts and related CMC activities.
Prior to joining Portola, Mr. Brame was vice president of supplier and contract manufacturing excellence for Genentech, where he was responsible for the transformation of quality, manufacturing, technical services, and supply chain operations for both biologics and small molecule products. During his tenure, Mr. Brame also served as vice president of global product quality and helped lead the successful start-ups of two new biologic manufacturing sites in Oregon and Singapore, as well as manufacturing and quality assurance for the product approvals of Kadcyla® and Erivedge®.
Previously, Mr. Brame was senior vice president of technical development and operations, leading a team of 1,200 professionals for Chiron Corporation and, upon its acquisition, Novartis. Earlier in his career, Mr. Brame held positions of increasing responsibility and leadership at Baxter BioScience where he served as both general manager and quality site head for large scale manufacturing plants, including a green field biologic drug substance and drug product start-up site in Switzerland.
Mr. Brame holds a B.S. from North Carolina State University and an M.B.A. from Delta State University.
Rajiv Patni, M.D.
Executive Vice President, Chief Medical Officer
Dr. Rajiv Patni joined Portola as executive vice president, chief medical officer in February 2020. In this role, Dr. Patni is responsible for clinical development and medical affairs. He brings two decades of clinical development experience, including 14 programs and eight approvals, across the cardiology, diabetology, dermato-oncology, hepatology, and neurology therapeutic areas.
Dr. Patni joined Portola from Adamas Pharmaceuticals, where he was Chief Medical Officer since 2015. During his tenure, he was responsible for the build-out of the R&D and medical affairs departments to support development programs in Parkinson’s Disease, multiple sclerosis, and epilepsy. These efforts resulted in the U.S. FDA approval of GOCOVRI.
Prior to Adamas, Dr. Patni was Chief Development Officer at Ocera Therapeutics, where he oversaw the development of ornithine phenylacetate to a Phase 2 data read-out in hepatic encephalopathy. Previously, he was Chief Medical Officer for the U.S. affiliate of Actelion Pharmaceuticals and contributed to the U.S. FDA approval and peri-launch medical affairs activities for OPSUMIT and UPTRAVI, both for pulmonary arterial hypertension, as well as VALCHLOR for cutaneous T-cell lymphoma. Earlier in his career, he held positions of increasing global responsibility in clinical development and medical affairs at Pfizer and Roche Pharmaceuticals.
Dr. Patni received the M.D. Degree from the Mount Sinai School of Medicine after completing his basic science (pre-clinical) studies at the Sophie Davis School of Biomedical Education, an accelerated B.S./M.D. Program in New York City. He completed a residency and fellowship in internal medicine and cardiology at the Albert Einstein College of Medicine, where he remained as an academic attending physician before joining industry.
Pamela Conley, Ph.D.
Senior Vice President of Research
Dr. Pamela Conley has more than 25 years’ experience discovering and developing both small molecule and biologic therapies for the treatment of cardiovascular disease, inflammation and cancer. Dr. Conley has been an integral part of the Portola team since its inception in 2003, taking on roles of increasing responsibility and contributing to the early- and late-stage development of the Company’s entire portfolio, including the U.S. FDA and European regulatory approvals of andexanet. In her current role, Dr. Conley is responsible for the early research and ongoing development of andexanet and cerdulatinib. Prior to Portola, Dr. Conley was a Senior Director of Biology at Millennium Pharmaceuticals, and a Director at Cor Therapeutics. Dr. Conley has authored more than 50 peer-reviewed manuscripts and is an inventor on multiple US patents.
She holds a B.S. in biochemistry from the University of Texas at Austin, a Ph.D. in biochemistry from University of California at Berkeley, and conducted postdoctoral research at Stanford University.
Our Board of Directors is comprised of leaders who offer the knowledge and experience required to navigate public biopharmaceutical companies, both large and small. Their deep expertise ranges from scientific and clinical to specialties in development, commercialization, operations, global expansion, finance and other proficiencies that successfully guide an organization seeking to profoundly change how life-threatening, blood-related disorders are treated.
Hollings C. Renton
Chairman of the Board
Hollings C. Renton previously served as president and chief executive officer, director, and chairman of the board of Onyx Pharmaceuticals, Inc. until he retired in 2008. From 1991 to 1993, he served as president and chief operating officer of Chiron Corporation, a pharmaceutical company, following its acquisition of Cetus Corporation. Prior to the acquisition, he served as president of Cetus Corporation from 1990 to 1991, as chief operating officer from 1987 to 1990, and as chief financial officer from 1983 to 1987. Mr. Renton currently serves as a director at AnaptysBio and Zymeworks Inc. He previously served as a director of Cepheid, Inc., Kythera Biopharmaceuticals, Rigel Pharmaceuticals, Inc., Affymax Inc., Sangstat Medical Corporation, Special Olympics Northern California, and the Biotechnology Industry Organization. Mr. Renton holds a B.S. in mathematics from Colorado State University and an M.B.A. from the University of Michigan.
Jeffrey Bird, M.D., Ph.D.
Managing Director, Sutter Hill Ventures
Jeffrey Bird, M.D., Ph.D., is a managing director at Sutter Hill Ventures, where he focuses on healthcare, including biotechnology and genomic technologies. Dr. Bird has been a board member of several public and private biotechnology companies over a 17-year investing career. Dr. Bird was previously senior vice president, business operations at Gilead Sciences Inc., where he worked for about 10 years and oversaw Gilead’s commercial sales and marketing teams, corporate development, and other functions. He received his B.S., M.D., and a Ph.D. in cancer biology from Stanford University.
Former President and Chief Executive Officer, Nodality, Inc.
Laura Brege is a senior advisor to BridgeBio Pharma, a clinical-stage biotechnology company developing novel, genetically targeted therapies. Previously, she was the president and chief executive officer of Nodality, Inc., a private company focused on innovative personalized medicine. Prior to joining Nodality in September 2012, Ms. Brege held several senior-level positions at Onyx Pharmaceuticals, Inc., from June 2006 to December 2011, including executive vice president and chief operating officer. While at Onyx, she led multiple functions, including commercialization, strategic planning, corporate development, and medical, scientific, and governmental affairs. Before joining Onyx, Ms. Brege was a general partner at Red Rock Capital Management Inc., a venture capital firm specializing in early stage financing for technology companies since 1999. Prior to Red Rock, she was the senior vice president and chief financial officer at COR Therapeutics Inc. Earlier in her career, Ms. Brege served as vice president and chief financial officer at Flextronics and vice president and treasurer of The Cooper Companies. In addition to Portola, Ms. Brege currently sits on the boards of directors of the public companies ACADIA Pharmaceuticals, Inc., Aratana Therapeutics, Inc., Dynavax Technologies and Pacira Pharmaceuticals, Inc. Ms. Brege earned her B.A. from Ohio University (Honors Tutorial College) and an M.B.A. from the University of Chicago.
Dennis Fenton, Ph.D.
Owner and Chief Executive Officer, Fenton and Associates
Dennis Fenton, Ph.D., is the owner and chief executive officer of Fenton and Associates, a biotechnology consulting firm. Prior to founding Fenton and Associates, Dr. Fenton served as executive vice president of operations at Amgen, where he was responsible for worldwide operations, manufacturing, process development, and quality. Dr. Fenton joined Amgen in 1982 and held numerous executive leadership roles in operations and sales and marketing. In addition to Portola, he serves on the board of Sienna and AnaptysBio. He also serves on the board of the Keck Graduate Institute. He previously served on the boards of Kythera, Hospira, Dendreon, Xenoport, and Genzyme. He received a B.S. from Manhattan College and a Ph.D. in microbiology from Rutgers University.
President and Chief Executive Officer
Mr. Garland joined Portola in October 2018 as president and chief executive officer. He brings more than 2 decades of broad executive leadership experience to Portola, including a strong track record driving multiple billion-dollar product launches. Mr. Garland joined Portola from Relypsa, Inc., where he was president and previously chief commercial officer. During his tenure, Mr. Garland was responsible for the integration and growth of the US operations after Relypsa was acquired by Vifor Pharma Group in 2016. Prior to Relypsa, Mr. Garland was executive vice president and chief commercial officer of Exelixis, Inc., where he led global commercial operations and directed sales, marketing and market access in the United States. Previously, Mr. Garland spent close to a decade at Genentech leading full-scale commercial franchises for 2 top-selling therapies, Avastin® (bevacizumab) and Rituxan® (rituximab). He started his career at Merck as a sales representative and then went on to serve at Amgen in various sales and marketing roles, including market development, to support the launch of Aranesp®(darbepoetin alfa). Mr. Garland has a B.S. in biological sciences from California Polytechnic State University, San Luis Obispo, and an M.B.A. from Duke University’s Fuqua School of Business. Mr. Garland is a member of the Board of Directors for Karyopharm Therapeutics, a company focused on hematologic diseases and oncology.
John H. Johnson
Former Chief Executive Officer, Melinta Therapeutics
John Johnson is a recognized leader in the pharmaceutical and biotechnology industry with more than 3 decades of experience. Mr. Johnson has held executive management roles at leading global corporations, including Johnson & Johnson, Eli Lilly & Company, ImClone Systems, Inc., Dendreon Corporation, Pfizer, Inc., and Melinta Therapeutics. He recently served as chief executive officer and a member of the board of directors of Melinta Therapeutics, as a member of the board of directors of Pharmaceutical Research and Manufacturers of America (PhRMA) and as a member of the Health Section Governing Board of the Biotechnology Industry Organization (BIO). He also served as chairman, president and chief executive officer of Dendreon and as chief executive officer and a member of the board of directors of Savient Pharmaceuticals, Inc. Prior to these roles, Mr. Johnson served as president of Eli Lilly & Company’s Oncology Unit, following the company’s 2008 acquisition of Imclone Systems, where he served as chief executive officer and a member of ImClone’s board of directors. Prior to Imclone, Mr. Johnson served as the company group chairman of Biopharmaceuticals within Johnson & Johnson, where he was responsible for the Johnson & Johnson Biotechnology, Immunology and Oncology commercial businesses. Prior to that role, Mr. Johnson held several executive positions at Johnson & Johnson, ParkStone Medical Information Systems, Inc., Ortho-McNeil Pharmaceutical Corp. and Pfizer, Inc. He previously served as chairman of Tranzyme Pharma, Inc., lead independent director at Sucampo Pharmaceuticals and as a member of the board of BioNJ. Mr. Johnson currently is chairman of Strongbridge Biopharma plc.
Ted Love, M.D.
President and Chief Executive Officer, Global Blood Therapeutics
Dr. Love is a recognized industry leader with more than 25 years’ experience in the discovery and development of innovative medicines. He currently serves as president and chief executive officer of Global Blood Therapeutics (GBT), and is a member of the Board of Directors. Previously, he was Executive Vice President and Head of Research and Development and Technical Operations at Onyx Pharmaceuticals, where he played an instrumental role in the development and approval of Kyprolis®. Prior to Onyx, Dr. Love served as president, chief executive officer and chairman of Nuvelo, Inc., and was previously senior vice president, development at Theravance, Inc. Earlier in his career, Dr. Love held a number of senior management positions at Genentech, where he oversaw the development strategy and execution leading to the approvals of Rituxan®, Herceptin®, Xolair®, TNKase®, Raptiva and Avastin®. Dr. Love holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School. He completed a residency in internal medicine and a fellowship in cardiology at the Massachusetts General Hospital. He currently serves on the board of directors of Amicus Therapeutics, Inc. and the Biotechnology Innovation Organization, and has served as a consultant in medicine in the Department of Cardiology at the Massachusetts General Hospital.
David C. Stump, M.D.
Former Executive Vice President, Research and Development, Human Genome Sciences, Inc.
David Stump, M.D., was most recently executive vice president, research and development at Human Genome Sciences, Inc., serving there from November 1999 until December 2012. Prior to joining Human Genome Sciences, Dr. Stump held roles of increasing responsibility at Genentech, Inc., from 1989 to 1999, most recently as vice president, clinical research, and was named a Genentech Fellow in 1996. Prior to joining Genentech, Dr. Stump was an associate professor of medicine and biochemistry at the University of Vermont. He is a member of the board of directors of Sunesis Pharmaceuticals, Inc., REGENXBIO, Inc., and MacroGenics Inc., and is a member of the board of trustees of Earlham College. He earned a B.A. from Earlham College and an M.D. at Indiana University, followed by residency and fellowship training in internal medicine, hematology and oncology, and biochemistry at the University of Iowa, then by further postgraduate training in hemostasis and thrombosis at the University of Leuven, Belgium. He is board certified in internal medicine, hematology, and medical oncology, and is a Fellow of the American College of Physicians and the Council on Arteriosclerosis, Thrombosis, and Vascular Biology of the American Heart Association.
H. Ward Wolff
Former Executive Vice President and Chief Financial Officer, Sangamo Therapeutics, Inc.
Ward Wolff was most recently executive vice president and chief financial officer of Sangamo Therapeutics, Inc., serving there from December 2007 until his retirement in March 2017. Mr. Wolff was formerly with Nuvelo, Inc., where he served as senior vice president, finance and chief financial officer until its restructuring in August 2007. Prior to joining Nuvelo, he was chief financial officer and senior vice president, finance, of Abgenix, Inc. until April 2006 when Abgenix merged with Amgen Inc. Prior to joining Abgenix, Mr. Wolff held financial management positions in both public and private emerging growth companies, including serving as senior vice president and chief financial officer of DoubleTwist, Inc., a life sciences company integrating genomic information and bioinformatics analysis tools. He began his career with Price Waterhouse, where he held a number of positions as a certified public accountant, including senior audit manager. In addition to Portola, he currently serves on the board of directors of Calithera Biosciences, Inc. and Sunesis Pharmaceuticals, Inc. Mr. Wolff received a B.A. in economics from the University of California, Berkeley, and an M.B.A. from Harvard Business School.
Portola’s Scientific Advisory Board provides advice on all aspects of therapeutic development—from unmet medical needs to new targets and paths, target validation, optimal indications, patient populations and trial design. Scientific Advisory Board members also help connect Portola to specific expertise as needed, and continually guide the company in ensuring its therapeutic programs are based on the best science and critical thinking.
Charles Esmon, Ph.D.
Head of the Coagulation Biology Laboratory at the Oklahoma Medical Research Foundation
Charles Esmon, Ph.D., is a member of the National Academy of Sciences, an investigator at the Howard Hughes Medical Institute, and head of the Coagulation Biology Laboratory at the Oklahoma Medical Research Foundation. Dr. Esmon has more than 300 publications related to blood coagulation and inflammation and has served as a consultant with a number of large and small pharmaceutical companies. Among his contributions in the coagulation area were the identification of thrombomodulin (with Dr. Whyte Owen) and endothelial protein C receptor (with Dr. Kenji Fukudome). In the field of sepsis, he and Dr. Fletcher Taylor were the first to show that activated protein C could prevent and treat septic animals challenged with normally lethal levels of bacteria. Most recently, Dr. Esmon has shown that cell death can trigger multi-organ failure by releasing DNA/histone complexes that cause multi-organ failure, a process that can be blocked by inhibiting the toxic histones.
David Ginsburg, M.D.
James V. Neel Distinguished University Professor of Internal Medicine and Human Genetics, and Warner-Lambert/Parke-Davis Professor of Medicine, University of Michigan Medical School, and a Howard Hughes Medical Institute Investigator
David Ginsburg, M.D., is a James V. Neel Distinguished University Professor of Internal Medicine and Human Genetics, Warner-Lambert/Parke-Davis Professor of Medicine and a member of the Life Sciences Institute at the University of Michigan Medical School. He also is a Howard Hughes Medical Institute Investigator. For the past 25 years, Dr. Ginsburg has dedicated his career to understanding the components of the blood-clotting system and how disturbances in their function lead to human bleeding and blood-clotting disorders. His lab has studied the molecular basis of the common disorder von Willebrand disease and is identifying modifier genes that control severity for this and related diseases. His lab has also defined mutations in ADAMTS13, an enzyme that processes von Willebrand factor, as the cause of thrombotic thrombocytopenia purpura. Studies of the bleeding disease combined deficiency of factors V and VIII by his lab identified mutations in a novel pathway for the transport of a select subset of proteins from the endoplasmic reticulum to the Golgi. Dr. Ginsburg is a member of the Institute of Medicine of the National Academy of Sciences and the American Academy of Arts and Sciences.
Frank McCormick, Ph.D.
Director, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center E. Dixon Heise Distinguished Professorship in Oncology and David A. Wood Distinguished Professorship of Tumor Biology and Cancer Research, University of California, San Francisco
Frank McCormick, Ph.D., is an internationally renowned molecular biologist and cancer researcher who helped pave the way toward the development of targeted cancer therapies. Dr. McCormick is director of the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center and has led the UCSF Cancer Center program since its inception in 1998. He holds the E. Dixon Heise Distinguished Professorship in Oncology and the David A. Wood Distinguished Professorship of Tumor Biology and Cancer Research at UCSF. He is also the associate dean of the UCSF School of Medicine and a distinguished Professor in Residence in the Department of Microbiology and Immunology as well as in the Department of Biochemistry and Biophysics. He is president-elect of the American Association for Cancer Research, an elected member of the Institute of Medicine of the National Academy of Sciences, and a Fellow of the Royal Society.
Arthur Weiss, M.D., Ph.D.
Chief, Rheumatology, University of California San Francisco
Director, Medical Scientist Training Program, University of California San Francisco
Arthur Weiss, M.D., Ph.D., is chief of the Division of Rheumatology and director of the Medical Scientist Training Program, both at the University of California San Francisco. Dr. Weiss was named an Ephraim P. Engleman Distinguished Professor and is a member of the US National Academy of Sciences, Institute of Medicine, and the American Academy of Arts and Sciences.